ZLAB · Zai Lab Ltd · Executive Compensation
$23.04
-0.54 (-2.29%)
At close · Oct 28
View the 10-Q filed Aug 6, 2026
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Customer concentration
— top customer 18% of receivables
One customer — 18% of receivables (As of June 30, 2026)
“As of June 30, 2026, our largest customer accounted for approximately 18% of our total accounts receivable collectively.”
Market Cap
$2.55B
Shares
112.27M
Volume · Oct 28
704.07K
Avg daily vol (3M)
1.03M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Rafael Amado | President, Head of Global Research and Development | $4,010,205 |
| Yajing Chen | Chief Financial Officer | $3,185,488 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Rafael Amado | President, Head of Global Research and Development | $3,645,791 |
| Yajing Chen | Chief Financial Officer | $2,625,170 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Josh Smiley | President and Chief Operating Officer | $5,550,550 |
| Joshua Smiley | President and Chief Operating Officer | $5,550,550 |
| Rafael Amado | President, Head of Global Research and Development | $4,865,822 |
| Billy Cho | Former Chief Financial Officer | $2,886,001 |
| Yajing Chen | Chief Financial Officer | $2,014,532 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joshua Smiley | President and Chief Operating Officer | $8,296,517 |
| Josh Smiley | President and Chief Operating Officer | $8,296,517 |
| Rafael Amado | President, Head of Global Research and Development | $7,501,706 |
| Alan Bart Sandler | Former President, Head of Global Development, Oncology | $7,329,748 |
| Billy Cho | Former Chief Financial Officer | $4,381,180 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Harald Reinhart | President, Head of Global Development, Neuroscience, Autoimmune, and Infectious Diseases. | $8,212,040 |
| Alan Bart Sandler | Former President, Head of Global Development, Oncology | $6,622,039 |
| F. Ty Edmondson | Chief Legal Officer | $5,629,054 |
| Billy Cho | Former Chief Financial Officer | $4,243,676 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Alan Bart Sandler | Former President, Head of Global Development, Oncology | $7,063,890 |
| F. Ty Edmondson | Chief Legal Officer | $4,408,928 |
| Billy Cho | Chief Financial Officer | $1,484,163 |
| Tao Fu | President and Chief Operating Officer | $649,770 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Rafael Amado | President, Head of Global Research and Development | Appointed | 2024-06-11 |
| Harald Reinhart | President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases | Retired | 2024-06-11 |
| Dr. Yajing Chen | Chief Financial Officer | Appointed | 2023-07-06 |
| Michel Vounatsos | independent director | Appointed | 2023-01-09 |
| Dr. Alan Sandler | Dr. Alan Sandler | Resigned | 2022-10-28 |
Leadership
- Dr. Yajing Chen CFO
- Yajing Chen CFO
- Josh Smiley COO
- John D. Diekman Board Member
- Leon O. Moulder Jr Board Member
- Michel Vounatsos Board Member
- Nisa Leung Board Member
- Peter Wirth Board Member
- Richard Gaynor Board Member
- Scott Morrison Board Member
- Scott W. Morrison Board Member
- William Lis Board Member